Radiation-response in primary fibroblasts of long-term survivors of childhood cancer with and without second primary neoplasms: the KiKme study.
Adult
Cancer Survivors
Case-Control Studies
Child
F-Box Proteins
Fibroblasts
/ radiation effects
Humans
Immediate-Early Proteins
Intracellular Signaling Peptides and Proteins
Neoplasms
Neoplasms, Second Primary
/ genetics
Nuclear Proteins
Receptors, Cytoplasmic and Nuclear
Sestrins
Tumor Suppressor Protein p53
Tumor Suppressor Proteins
Differential gene expression
High dose
Low dose
NGS
Pathway analysis
RNA-Seq
Radiation experiment
Radiation response
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
06 09 2022
06 09 2022
Historique:
received:
21
01
2022
accepted:
28
07
2022
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
The etiology and most risk factors for a sporadic first primary neoplasm in childhood or subsequent second primary neoplasms are still unknown. One established causal factor for therapy-associated second primary neoplasms is the exposure to ionizing radiation during radiation therapy as a mainstay of cancer treatment. Second primary neoplasms occur in 8% of all cancer survivors within 30 years after the first diagnosis in Germany, but the underlying factors for intrinsic susceptibilities have not yet been clarified. Thus, the purpose of this nested case-control study was the investigation and comparison of gene expression and affected pathways in primary fibroblasts of childhood cancer survivors with a first primary neoplasm only or with at least one subsequent second primary neoplasm, and controls without neoplasms after exposure to a low and a high dose of ionizing radiation. Primary fibroblasts were obtained from skin biopsies from 52 adult donors with a first primary neoplasm in childhood (N1), 52 with at least one additional primary neoplasm (N2+), as well as 52 without cancer (N0) from the KiKme study. Cultured fibroblasts were exposed to a high [2 Gray (Gy)] and a low dose (0.05 Gy) of X-rays. Messenger ribonucleic acid was extracted 4 h after exposure and Illumina-sequenced. Differentially expressed genes (DEGs) were computed using limma for R, selected at a false discovery rate level of 0.05, and further analyzed for pathway enrichment (right-tailed Fisher's Exact Test) and (in-) activation (z ≥|2|) using Ingenuity Pathway Analysis. After 0.05 Gy, least DEGs were found in N0 (n = 236), compared to N1 (n = 653) and N2+ (n = 694). The top DEGs with regard to the adjusted p-value were upregulated in fibroblasts across all donor groups (SESN1, MDM2, CDKN1A, TIGAR, BTG2, BLOC1S2, PPM1D, PHLDB3, FBXO22, AEN, TRIAP1, and POLH). Here, we observed activation of p53 Signaling in N0 and to a lesser extent in N1, but not in N2+. Only in N0, DNA (excision-) repair (involved genes: CDKN1A, PPM1D, and DDB2) was predicted to be a downstream function, while molecular networks in N2+ were associated with cancer, as well as injury and abnormalities (among others, downregulation of MSH6, CCNE2, and CHUK). After 2 Gy, the number of DEGs was similar in fibroblasts of all donor groups and genes with the highest absolute log Our results show dose-dependent differences in the radiation response between N1/N2+ and N0. While mechanisms against genotoxic stress were activated to the same extent after a high dose in all groups, the radiation response was impaired after a low dose in N1/N2+, suggesting an increased risk for adverse effects including carcinogenesis, particularly in N2+.
Sections du résumé
BACKGROUND
The etiology and most risk factors for a sporadic first primary neoplasm in childhood or subsequent second primary neoplasms are still unknown. One established causal factor for therapy-associated second primary neoplasms is the exposure to ionizing radiation during radiation therapy as a mainstay of cancer treatment. Second primary neoplasms occur in 8% of all cancer survivors within 30 years after the first diagnosis in Germany, but the underlying factors for intrinsic susceptibilities have not yet been clarified. Thus, the purpose of this nested case-control study was the investigation and comparison of gene expression and affected pathways in primary fibroblasts of childhood cancer survivors with a first primary neoplasm only or with at least one subsequent second primary neoplasm, and controls without neoplasms after exposure to a low and a high dose of ionizing radiation.
METHODS
Primary fibroblasts were obtained from skin biopsies from 52 adult donors with a first primary neoplasm in childhood (N1), 52 with at least one additional primary neoplasm (N2+), as well as 52 without cancer (N0) from the KiKme study. Cultured fibroblasts were exposed to a high [2 Gray (Gy)] and a low dose (0.05 Gy) of X-rays. Messenger ribonucleic acid was extracted 4 h after exposure and Illumina-sequenced. Differentially expressed genes (DEGs) were computed using limma for R, selected at a false discovery rate level of 0.05, and further analyzed for pathway enrichment (right-tailed Fisher's Exact Test) and (in-) activation (z ≥|2|) using Ingenuity Pathway Analysis.
RESULTS
After 0.05 Gy, least DEGs were found in N0 (n = 236), compared to N1 (n = 653) and N2+ (n = 694). The top DEGs with regard to the adjusted p-value were upregulated in fibroblasts across all donor groups (SESN1, MDM2, CDKN1A, TIGAR, BTG2, BLOC1S2, PPM1D, PHLDB3, FBXO22, AEN, TRIAP1, and POLH). Here, we observed activation of p53 Signaling in N0 and to a lesser extent in N1, but not in N2+. Only in N0, DNA (excision-) repair (involved genes: CDKN1A, PPM1D, and DDB2) was predicted to be a downstream function, while molecular networks in N2+ were associated with cancer, as well as injury and abnormalities (among others, downregulation of MSH6, CCNE2, and CHUK). After 2 Gy, the number of DEGs was similar in fibroblasts of all donor groups and genes with the highest absolute log
CONCLUSION
Our results show dose-dependent differences in the radiation response between N1/N2+ and N0. While mechanisms against genotoxic stress were activated to the same extent after a high dose in all groups, the radiation response was impaired after a low dose in N1/N2+, suggesting an increased risk for adverse effects including carcinogenesis, particularly in N2+.
Identifiants
pubmed: 36068491
doi: 10.1186/s10020-022-00520-6
pii: 10.1186/s10020-022-00520-6
pmc: PMC9450413
doi:
Substances chimiques
F-Box Proteins
0
FBXO22 protein, human
0
Immediate-Early Proteins
0
Intracellular Signaling Peptides and Proteins
0
Nuclear Proteins
0
Receptors, Cytoplasmic and Nuclear
0
SESN2 protein, human
0
Sestrins
0
TRIAP1 protein, human
0
Tumor Suppressor Protein p53
0
Tumor Suppressor Proteins
0
BTG2 protein, human
141490-22-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105Informations de copyright
© 2022. The Author(s).
Références
BMC Med Genomics. 2008 Dec 24;1:63
pubmed: 19108712
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10690-5
pubmed: 19541625
Mol Med. 2020 Sep 9;26(1):85
pubmed: 32907548
PLoS One. 2011;6(7):e21800
pubmed: 21789182
Radiat Res. 2016 Nov;186(5):531-538
pubmed: 27802111
BMC Bioinformatics. 2012 Jun 18;13:134
pubmed: 22708584
Lancet. 2012 Aug 4;380(9840):499-505
pubmed: 22681860
Health Aff (Millwood). 2008 Nov-Dec;27(6):1491-502
pubmed: 18997204
Cancer Treat Rev. 2010 Nov;36(7):518-27
pubmed: 20413225
Haematologica. 2018 Feb;103(2):313-324
pubmed: 29122990
Biochem Pharmacol. 1998 Apr 1;55(7):941-51
pubmed: 9605418
Dose Response. 2019 Feb 26;17(1):1559325819833488
pubmed: 30833876
Radiother Oncol. 2016 May;119(2):236-43
pubmed: 26987471
Semin Cancer Biol. 2016 Jun;37-38:77-95
pubmed: 26873647
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Radiat Oncol J. 2018 Jun;36(2):85-94
pubmed: 29983028
Cell. 2019 Jan 24;176(3):491-504.e21
pubmed: 30612740
Cancer Res. 2005 Sep 1;65(17):7666-73
pubmed: 16140933
J Cell Biochem. 2019 Nov 10;:
pubmed: 31709644
Environ Health Perspect. 2015 Jun;123(6):622-8
pubmed: 25707026
Arch Toxicol. 2020 May;94(5):1511-1549
pubmed: 32399610
Leuk Lymphoma. 2017 Jan;58(1):70-79
pubmed: 27185377
Front Immunol. 2019 Dec 04;10:2797
pubmed: 31867002
Genes Environ. 2018 Dec 19;40:26
pubmed: 30598710
Radiat Res. 2011 Jun;175(6):677-88
pubmed: 21486161
Int J Environ Res Public Health. 2016 Oct 28;13(11):
pubmed: 27801855
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Health Phys. 1982 Dec;43(6):771-89
pubmed: 6759465
N Engl J Med. 1988 Oct 20;319(16):1033-9
pubmed: 3173432
Lancet Haematol. 2018 Aug;5(8):e346-e358
pubmed: 30026010
Radiat Res. 2005 Jul;164(1):17-26
pubmed: 15966761
Int J Mol Sci. 2016 Jan 14;17(1):
pubmed: 26784176
Int J Mol Sci. 2015 Dec 31;17(1):
pubmed: 26729107
Environ Mol Mutagen. 2017 Oct;58(8):560-569
pubmed: 28856770
Nat Med. 2004 Aug;10(8):789-99
pubmed: 15286780
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):800-7
pubmed: 26972653
Gene. 2015 Oct 1;570(1):8-16
pubmed: 26071189
J Biol Chem. 2016 Aug 26;291(35):18440-52
pubmed: 27402838
Cancer Res. 1991 Jun 1;51(11):2885-8
pubmed: 1851664
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Dose Response. 2018 Jul 01;16(3):1559325818779651
pubmed: 30013457
Curr Med Chem. 2016;23(34):3951-3963
pubmed: 27554808
Pediatr Hematol Oncol. 2013 Feb;30(1):33-45
pubmed: 23140311
Toxicol Res (Camb). 2015 Aug 11;5(1):12-33
pubmed: 30090323
Int J Radiat Biol. 2013 Aug;89(8):628-38
pubmed: 23484538
Oncogene. 2011 Apr 14;30(15):1812-21
pubmed: 21242979
BMC Med Genomics. 2015 May 12;8:22
pubmed: 25963628
Science. 1997 Apr 4;276(5309):111-3
pubmed: 9082980
Mol Biol Rep. 2012 Jul;39(7):7549-58
pubmed: 22367372
J Radiat Res. 2012 Nov 1;53(6):860-75
pubmed: 22915785
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):339-46
pubmed: 20646844
CA Cancer J Clin. 2012 Mar-Apr;62(2):75-100
pubmed: 22307864
Pediatr Clin North Am. 2015 Feb;62(1):11-25
pubmed: 25435109
Dose Response. 2015 May 04;13(1):
pubmed: 26675169
Nat Rev Mol Cell Biol. 2014 Jul;15(7):433-52
pubmed: 24954208
Br J Cancer. 2016 Feb 16;114(4):388-94
pubmed: 26882064
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
J Natl Cancer Inst. 2012 Mar 7;104(5):357-70
pubmed: 22312134
Am Soc Clin Oncol Educ Book. 2017;37:736-745
pubmed: 28561716
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):876-83
pubmed: 19386434
Cancer. 1980 Dec 15;46(12):2603-6
pubmed: 7448699
Radiat Res. 2009 Jul;172(1):82-95
pubmed: 19580510
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cell. 2006 May 5;125(3):453-66
pubmed: 16678093
BMC Genomics. 2012 May 17;13:190
pubmed: 22594378
Radiat Res. 2012 Jan;177(1):69-83
pubmed: 22029842
Cold Spring Harb Protoc. 2015 Apr 13;2015(11):951-69
pubmed: 25870306
Nucleic Acids Res. 2013 Jan;41(Database issue):D793-800
pubmed: 23143270
PLoS One. 2015 Apr 17;10(4):e0123316
pubmed: 25886619
Enzymes. 2019;45:99-138
pubmed: 31627884
JMIR Res Protoc. 2021 Nov 11;10(11):e32395
pubmed: 34762066
Elife. 2014 Sep 16;3:e03164
pubmed: 25233275
Hum Genet. 1986 Aug;73(4):320-6
pubmed: 3017841
Int J Radiat Biol. 2013 May;89(5):326-33
pubmed: 23216318
Transl Pediatr. 2015 Apr;4(2):67-75
pubmed: 26835363
PLoS One. 2011;6(10):e25750
pubmed: 21991345
Dtsch Arztebl Int. 2018 Jun 8;115(23):385-392
pubmed: 29960606
Nucleic Acids Res. 2009 Apr;37(6):e45
pubmed: 19237396
Int J Radiat Biol. 2011 Feb;87(2):115-29
pubmed: 21067298
Translation (Austin). 2016 Dec 1;5(1):e1265703
pubmed: 28702276
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):229-34
pubmed: 17996396
Tumour Biol. 2014 Apr;35(4):3525-34
pubmed: 24338765